Researchers from Lawrence Livermore National Laboratory (LLNL), in collaboration with other leading institutions, have successfully used an AI-driven platform to preemptively optimize an antibody to neutralize a broad diversity of SARS-CoV-2 variants.
AI optimizes antibodies to tackle evolving SARS-CoV-2 variants
-
HighlightsFree Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
HighlightsSmart buildings: What happens to our free will when tech makes choices for us?
-
AppsScreenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
HighlightsDarknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
SecurityPrivacy violations undermine the trustworthiness of the Tim Hortons brand
-
Featured HeadlinesWhy Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars
